| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 5697707 | Clinical Oncology | 2017 | 7 Pages | 
Abstract
												Due to a lack of empirical research, few evidenced-based recommendations could be made with respect to a follow-up schedule of PSA testing for prostate cancer survivors following curative-intent treatment, or detailing diagnostic testing upon detection of biochemical recurrence. Accordingly, the GDG focused substantial effort on critical examination of the identified evidence, existing clinical practice guidelines and on obtaining clinical expertise consensus using a modified Delphi method. Overall, the recommendations embedded in this guideline reflect the best practice to date for the efficient and effective clinical follow-up care of prostate cancer survivors.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												A. Loblaw, L.H. Souter, C. Canil, R.H. Breau, M. Haider, L. Jamnicky, R. Morash, M. Surchin, A. Matthew, 
											